Literature DB >> 11267934

Sex hormone dependency of diethylnitrosamine-induced liver tumors in mice and chemoprevention by leuprorelin.

T Nakatani1, G Roy, N Fujimoto, T Asahara, A Ito.   

Abstract

The prevalence of liver tumors throughout the world makes it imperative to seek chemopreventive agents. This tumor appears to be hormone-responsive and hormonal manipulations may therefore be beneficial. On this basis, both sexes of 12-day-old B6C3F(1) mice were injected i.p. with diethylnitrosamine (DEN) at the dose of 2.5 mg / g body weight and observed for 32 weeks (males) or 36 weeks (females). In 100% of male mice, liver tumors were observed with an average diameter of 2.72 mm and multiplicity of 60.8. Orchidectomy at 6 weeks of age in these mice inhibited the incidence, multiplicity and size to 63%, 5.6 and 1.54 mm, respectively. By further implantation with an E(2) pellet at monthly intervals, these parameters were reduced to 26%, 0.6 and 0.61 mm, respectively. Administration of a gonadotropin-blocking chemical, leuprorelin, to DEN-treated male mice significantly reduced the multiplicity and size of tumors to 18.3 and 2.54 mm (P < 0.01 compared to those of DEN only). In female mice, the incidence of liver tumor was significantly smaller than that of males. However, ovariectomy and / or testosterone supplement significantly increased the occurrence of liver tumor. An anti-estrogen, toremifene, caused a marked further decrease of liver tumors. Mitotic indices with bromodeoxyuridine in tumor tissues paralleled the occurrence of liver tumors. Serum testosterone levels were significantly reduced by orchidectomy or by leuprorelin administration. These results further confirm that liver tumor is testosterone-responsive and hormonal manipulation by surgical orchidectomy or by chemical orchidectomy i.e. by leuprorelin, could substantially prevent the appearance of liver tumors.

Entities:  

Mesh:

Substances:

Year:  2001        PMID: 11267934      PMCID: PMC5926710          DOI: 10.1111/j.1349-7006.2001.tb01089.x

Source DB:  PubMed          Journal:  Jpn J Cancer Res        ISSN: 0910-5050


  36 in total

Review 1.  Active cell death in hormone-dependent tissues.

Authors:  M P Tenniswood; R S Guenette; J Lakins; M Mooibroek; P Wong; J E Welsh
Journal:  Cancer Metastasis Rev       Date:  1992-09       Impact factor: 9.264

2.  Failure of ketoconazole as anti-androgen therapy in nonresectable primary hepatocellular carcinoma.

Authors:  S Gupta; J Korula
Journal:  J Clin Gastroenterol       Date:  1988-12       Impact factor: 3.062

3.  Aflatoxin carcinogenesis: inhibition of liver cancer induction in hypophysectomized rats.

Authors:  C M Goodall; W H Butler
Journal:  Int J Cancer       Date:  1969-07-15       Impact factor: 7.396

4.  Effects of castration and androgen replacement on tumour growth of human hepatocellular carcinoma in nude mice.

Authors:  L Yu; N Nagasue; M Yamaguchi; Y C Chang
Journal:  J Hepatol       Date:  1996-09       Impact factor: 25.083

5.  Relevance of basophilic foci to promoting effect of sex hormones on hepatocarcinogenesis.

Authors:  S D Vesselinovitch; N Mihailovich; K V Rao; S Goldfarb
Journal:  Carcinog Compr Surv       Date:  1982

6.  Loss of tumor-promoting activity of unleaded gasoline in N-nitrosodiethylamine-initiated ovariectomized B6C3F1 mouse liver.

Authors:  G J Moser; D C Wolf; B A Wong; T L Goldsworthy
Journal:  Carcinogenesis       Date:  1997-05       Impact factor: 4.944

7.  Regression of rat mammary tumors effected by a gonadoliberin analog.

Authors:  E R DeSombre; E S Johnson; W F White
Journal:  Cancer Res       Date:  1976-10       Impact factor: 12.701

8.  The effect of several sex steroid hormones on the growth rate of three Morris hepatoma tumor lines.

Authors:  J Erdstein; S Wisebord; S Y Mishkin; S Mishkin
Journal:  Hepatology       Date:  1989-04       Impact factor: 17.425

9.  Evaluation of hepatocellular neoplasms in mice.

Authors:  J M Ward; G Vlahakis
Journal:  J Natl Cancer Inst       Date:  1978-09       Impact factor: 13.506

10.  Regression of rat mammary tumors by a potent luteinizing hormone-releasing hormone analogue (leuprolide) administered vaginally.

Authors:  H Okada; Y Sakura; H Kawaji; T Yashiki; H Mima
Journal:  Cancer Res       Date:  1983-04       Impact factor: 12.701

View more
  43 in total

1.  Igf1 expression in mouse model of liver carcinogenesis.

Authors:  L S Zinevich; A S Mikaelyan
Journal:  Dokl Biochem Biophys       Date:  2012-03-15       Impact factor: 0.788

Review 2.  The Estrogen Receptor α-Cistrome Beyond Breast Cancer.

Authors:  Marjolein Droog; Mark Mensink; Wilbert Zwart
Journal:  Mol Endocrinol       Date:  2016-08-04

3.  The role for estrogen receptor-alpha and prolactin receptor in sex-dependent DEN-induced liver tumorigenesis.

Authors:  Robert M Bigsby; Andrea Caperell-Grant
Journal:  Carcinogenesis       Date:  2011-05-23       Impact factor: 4.944

4.  Differential Proteomic Analysis of Gender-dependent Hepatic Tumorigenesis in Hras12V Transgenic Mice.

Authors:  Zhuona Rong; Tingting Fan; Huiling Li; Juan Li; Kangwei Wang; Xinxin Wang; Jianyi Dong; Jun Chen; Fujin Wang; Jingyu Wang; Aiguo Wang
Journal:  Mol Cell Proteomics       Date:  2017-05-16       Impact factor: 5.911

5.  Curcumin, a cancer chemopreventive and chemotherapeutic agent, is a biologically active iron chelator.

Authors:  Yan Jiao; John Wilkinson; Xiumin Di; Wei Wang; Heather Hatcher; Nancy D Kock; Ralph D'Agostino; Mary Ann Knovich; Frank M Torti; Suzy V Torti
Journal:  Blood       Date:  2008-09-24       Impact factor: 22.113

6.  Gender-related distribution of the interleukin-1 beta and interleukin-1 receptor antagonist gene polymorphisms in patients with end-stage liver disease.

Authors:  Elisabetta Fontanini; Annarosa Cussigh; Carlo Fabris; Edmondo Falleti; Pierluigi Toniutto; Davide Bitetto; Sara Cmet; Elisa Fumolo; Ezio Fornasiere; Sara Bignulin; David J Pinato; Rosalba Minisini; Mario Pirisi
Journal:  Inflammation       Date:  2010-08       Impact factor: 4.092

7.  Estrogen represses hepatocellular carcinoma (HCC) growth via inhibiting alternative activation of tumor-associated macrophages (TAMs).

Authors:  Weiwei Yang; Yan Lu; Yichen Xu; Lizhi Xu; Wei Zheng; Yuanyuan Wu; Long Li; Pingping Shen
Journal:  J Biol Chem       Date:  2012-08-20       Impact factor: 5.157

Review 8.  Androgen receptor roles in hepatocellular carcinoma, fatty liver, cirrhosis and hepatitis.

Authors:  Wen-Lung Ma; Hsueh-Chou Lai; Shuyuan Yeh; Xiujun Cai; Chawnshang Chang
Journal:  Endocr Relat Cancer       Date:  2014-05-06       Impact factor: 5.678

Review 9.  Experimental mouse models for hepatocellular carcinoma research.

Authors:  Femke Heindryckx; Isabelle Colle; Hans Van Vlierberghe
Journal:  Int J Exp Pathol       Date:  2009-08       Impact factor: 1.925

10.  MicroRNA expression, survival, and response to interferon in liver cancer.

Authors:  Junfang Ji; Jiong Shi; Anuradha Budhu; Zhipeng Yu; Marshonna Forgues; Stephanie Roessler; Stefan Ambs; Yidong Chen; Paul S Meltzer; Carlo M Croce; Lun-Xiu Qin; Kwan Man; Chung-Mau Lo; Joyce Lee; Irene O L Ng; Jia Fan; Zhao-You Tang; Hui-Chuan Sun; Xin Wei Wang
Journal:  N Engl J Med       Date:  2009-10-08       Impact factor: 91.245

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.